Viking Therapeutics Sees Growing Strategic Interest in $150 Billion Weight-Loss Drug Market 
Dollar Steadies Ahead of ECB and BoE Decisions as Markets Turn Risk-Off 
Singapore Budget 2026 Set for Fiscal Prudence as Growth Remains Resilient 
Nvidia Nears $20 Billion OpenAI Investment as AI Funding Race Intensifies 
Global Markets Slide as AI, Crypto, and Precious Metals Face Heightened Volatility 
Bank of Japan Signals Readiness for Near-Term Rate Hike as Inflation Nears Target 
South Korea Assures U.S. on Trade Deal Commitments Amid Tariff Concerns 
Neuralink Expands Brain Implant Trials with 12 Global Patients 
FDA Fast-Track Drug Reviews Delayed Over Safety and Efficacy Concerns 
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
NASA Resumes Cygnus XL Cargo Docking with Space Station After Software Fix 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
Trump Signs Executive Order to Boost AI Research in Childhood Cancer 
Trump Administration to Launch Autism Initiatives Targeting Acetaminophen Use and New Treatment Options 
California Jury Awards $40 Million in Johnson & Johnson Talc Cancer Lawsuit 
A South Korean research team has developed a strip-type urine test that successfully diagnoses prostate and pancreatic cancer on-site by amplifying the optical signal of the metabolome in urine.
The joint research team is from the Korea Institute of Materials Science, Pohang University of Science and Technology, and Kyung Hee University
The surface-enhanced Raman scattering sensor that they developed can amplify the optical signal of the metabolome in urine by more than 1 billion times by forming a coral reef-shaped plasmonic nanomaterial on top of porous paper material.
A light irradiation after a 10-microliter urine droplet amplified signal of cancer metabolome on the sensor’s surface without the need to go through a separate analysis process,.
The application of an artificial intelligence-based analytical method for the spectrum signal generated through the irradiation of light into the urine can identify people with prostate cancer and pancreatic cancer with an accuracy of up to 99 percent.
